Ascend Capital’s Esperion Therapeutics ESPR Stock Holding History

Ascend Capital’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-67,241	Closed	-$4.43M	–	225
2017 Q4	$4.43M	Buy	+67,241	New	+$3.62M	0.17%	130

Other funds holding ESPR

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ascend Capital's ESPR Position: Q1 2018 in Review

Ascend Capital sold out of Esperion Therapeutics (ESPR) in Q1 2018, closing a stake of 67,241 shares — an estimated $4.43M sold.

Ascend Capital first reported a position in ESPR in Q4 2017 and held it in 1 quarter. The position peaked at $4.43M in Q4 2017. 187 funds tracked by Wall St. Rank hold ESPR as of Q1 2018.

Ascend Capital reported no remaining Esperion Therapeutics position as of Q1 2018 after selling out during the quarter.
Ascend Capital sold 67,241 Esperion Therapeutics shares in Q1 2018, an estimated $4.43M.
Ascend Capital first reported a position in Esperion Therapeutics in Q4 2017 and held it in 1 quarter.
Ascend Capital's Esperion Therapeutics position peaked at $4.43M in Q4 2017.
187 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2018.

Based on Ascend Capital's 13F filing for Q1 2018, filed 14 May 2018.